ASX health stocks: 4D Medical leads after ramping up its game in the US
Health & Biotech
share clipboard
ASX 200 health stocks index rose by 0.68% this morning, compared to the broader index which rose by 0.24%.
Respiratory device specialist,
In its quarterly update, the company said it has ramped up commercialisation activities following the rapidly growing vaccination uptake in the US.
This, 4DX says, will allow for greater access to key decision makers at hospitals and medical institutions, where it plans to commence several clinical trials for its of XV Lung Ventilation Analysis Software (XV LVAS).
4DX also reported a cash balance of $80.9 million as at 30 June, with net operating cash outflows for the quarter of $0.6 million, which includes $7.1 million received in government grants and tax incentives and $0.6 million in receipts from customers.